2.43
Schlusskurs vom Vortag:
$2.57
Offen:
$2.6
24-Stunden-Volumen:
734.30K
Relative Volume:
0.31
Marktkapitalisierung:
$260.06M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-4.6731
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+1.67%
1M Leistung:
-3.95%
6M Leistung:
+99.18%
1J Leistung:
+113.16%
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ACRS
Aclaris Therapeutics Inc
|
2.43 | 260.06M | 27.08M | -37.00M | -18.46M | -0.52 |
![]()
TMO
Thermo Fisher Scientific Inc
|
572.71 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
![]()
DHR
Danaher Corp
|
210.01 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
![]()
A
Agilent Technologies Inc
|
147.64 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
![]()
IQV
Iqvia Holdings Inc
|
209.96 | 38.11B | 15.32B | 1.41B | 1.96B | 7.62 |
![]()
IDXX
Idexx Laboratories Inc
|
460.56 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
2022-12-14 | Eingeleitet | Stifel | Buy |
2022-12-01 | Eingeleitet | Goldman | Buy |
2022-10-06 | Eingeleitet | BTIG Research | Buy |
2021-07-23 | Fortgesetzt | Jefferies | Buy |
2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
2018-02-09 | Eingeleitet | Guggenheim | Buy |
2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
2016-06-10 | Eingeleitet | Guggenheim | Buy |
2015-11-02 | Eingeleitet | Citigroup | Buy |
2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
What is Leerink Partnrs’ Forecast for ACRS FY2025 Earnings? - Armenian Reporter
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Analysts - MarketBeat
Aclaris Therapeutics Inc [ACRS] Records 50-Day SMA of $2.98 - Knox Daily
Aclaris Therapeutics forms new Scientific Advisory Board - MSN
The Aclaris Therapeutics Inc (ACRS) had a good session last reading, didn’t it? - US Post News
Aclaris Therapeutics Inc (ACRS)’s Market Momentum: Closing Strong at 2.40, Down -3.23 - The Dwinnex
Healthy Upside Potential: Aclaris Therapeutics Inc (ACRS) - SETE News
Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Cantor Fitzgerald - Defense World
Aclaris Therapeutics Forms Scientific Advisory Board with Renowned Pulmonology Experts - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in January - Defense World
StockNews.com Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to Sell - Defense World
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - GlobeNewswire
Aclaris Therapeutics forms new Scientific Advisory Board By Investing.com - Investing.com Canada
Aclaris Therapeutics Appoints Marianne Mann and Zuzana Diamant to Scientific Advisory Board - citybiz
Assenagon Asset Management S.A. Acquires 211,585 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Cantor Fitzgerald Comments on ACRS FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on ACRS FY2025 Earnings - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in December - MarketBeat
Hair Treatment Drug Market Is Booming Worldwide | 3S Bio, Inc.,AbbVie,Aclaris Therapeutics, Inc.,Cipla, Inc. - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.00 Average Target Price from Brokerages - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Jane Street Group LLC - MarketBeat
Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Highlights Drug Progress and Financial Strength - TipRanks
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Awards Stock Options to Attract Top Talent - MSN
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Hair Loss Treatment Market Is Booming Worldwide 2024-2031 | Viviscal, Cipla Inc., Aclaris Therapeutics - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by State Street Corp - Defense World
Aclaris sells OLUMIANT royalties and milestones to OMERS life sciences - MSN
HC Wainwright & Co. Upgrades Aclaris Therapeutics (ACRS) - MSN
ACRS LOSS NOTICE: ROSEN, A LEADING FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the FirmACRS - AccessWire
INVESTOR ALERTAclaris Therapeutics, Inc. (ACRS)Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 - AccessWire
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Update - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 27.4% in December - MarketBeat
Research Analysts Issue Forecasts for ACRS FY2024 Earnings - Defense World
HC Wainwright Has Bullish Estimate for ACRS FY2024 Earnings - MarketBeat
Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma - Investing.com Nigeria
Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma By Investing.com - Investing.com South Africa
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Buy at HC Wainwright - Defense World
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aclaris Therapeutics Inc-Aktie (ACRS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):